BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 29061848)

  • 21. Herpes simplex virus glycoprotein D interferes with binding of herpesvirus entry mediator to its ligands through downregulation and direct competition.
    Stiles KM; Whitbeck JC; Lou H; Cohen GH; Eisenberg RJ; Krummenacher C
    J Virol; 2010 Nov; 84(22):11646-60. PubMed ID: 20826693
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Structural determinants of herpesvirus entry mediator recognition by murine B and T lymphocyte attenuator.
    Nelson CA; Fremont MD; Sedy JR; Norris PS; Ware CF; Murphy KM; Fremont DH
    J Immunol; 2008 Jan; 180(2):940-7. PubMed ID: 18178834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B- and T-Lymphocyte Attenuator in Systemic Lupus Erythematosus Disease Pathogenesis.
    Vendel AC; Jaroszewski L; Linnik MD; Godzik A
    Clin Pharmacol Ther; 2024 Jul; 116(1):247-256. PubMed ID: 38676311
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design of short peptides to block BTLA/HVEM interactions for promoting anticancer T-cell responses.
    Spodzieja M; Lach S; Iwaszkiewicz J; Cesson V; Kalejta K; Olive D; Michielin O; Speiser DE; Zoete V; Derré L; Rodziewicz-Motowidło S
    PLoS One; 2017; 12(6):e0179201. PubMed ID: 28594868
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Slow down and survive: Enigmatic immunoregulation by BTLA and HVEM.
    Murphy TL; Murphy KM
    Annu Rev Immunol; 2010; 28():389-411. PubMed ID: 20307212
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A coreceptor interaction between the CD28 and TNF receptor family members B and T lymphocyte attenuator and herpesvirus entry mediator.
    Gonzalez LC; Loyet KM; Calemine-Fenaux J; Chauhan V; Wranik B; Ouyang W; Eaton DL
    Proc Natl Acad Sci U S A; 2005 Jan; 102(4):1116-21. PubMed ID: 15647361
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modulation of cytotoxic responses by targeting CD160 prolongs skin graft survival across major histocompatibility class I barrier.
    Del Rio ML; Bravo Moral AM; Fernandez-Renedo C; Buhler L; Perez-Simon JA; Chaloin O; Alvarez Nogal R; Fernandez-Caso M; Rodriguez-Barbosa JI
    Transl Res; 2017 Mar; 181():83-95.e3. PubMed ID: 27702550
    [TBL] [Abstract][Full Text] [Related]  

  • 28. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator.
    Sedy JR; Gavrieli M; Potter KG; Hurchla MA; Lindsley RC; Hildner K; Scheu S; Pfeffer K; Ware CF; Murphy TL; Murphy KM
    Nat Immunol; 2005 Jan; 6(1):90-8. PubMed ID: 15568026
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Loss of the HVEM Tumor Suppressor in Lymphoma and Restoration by Modified CAR-T Cells.
    Boice M; Salloum D; Mourcin F; Sanghvi V; Amin R; Oricchio E; Jiang M; Mottok A; Denis-Lagache N; Ciriello G; Tam W; Teruya-Feldstein J; de Stanchina E; Chan WC; Malek SN; Ennishi D; Brentjens RJ; Gascoyne RD; Cogné M; Tarte K; Wendel HG
    Cell; 2016 Oct; 167(2):405-418.e13. PubMed ID: 27693350
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD160 isoforms and regulation of CD4 and CD8 T-cell responses.
    El-Far M; Pellerin C; Pilote L; Fortin JF; Lessard IA; Peretz Y; Wardrop E; Salois P; Bethell RC; Cordingley MG; Kukolj G
    J Transl Med; 2014 Sep; 12():217. PubMed ID: 25179432
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular cloning and characterization of TNFSF14 (LIGHT) and its receptor TNFRSF14 (HVEM) in guinea pig (Cavia porcellus).
    Li C; Chen S; Song J; Liu H; Gu W; Ai H; Zhao B; Zhang S
    Gene; 2013 Sep; 526(2):374-84. PubMed ID: 23732292
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Regulatory T cell expression of herpesvirus entry mediator suppresses the function of B and T lymphocyte attenuator-positive effector T cells.
    Tao R; Wang L; Murphy KM; Fraser CC; Hancock WW
    J Immunol; 2008 May; 180(10):6649-55. PubMed ID: 18453584
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors.
    Demerlé C; Gorvel L; Mello M; Pastor S; Degos C; Zarubica A; Angelis F; Fiore F; Nunes JA; Malissen B; Greillier L; Guittard G; Luche H; Barlesi F; Olive D
    J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37230538
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epitope topography of agonist antibodies to the checkpoint inhibitory receptor BTLA.
    Cheung TC; Atwell S; Bafetti L; Cuenca PD; Froning K; Hendle J; Hickey M; Ho C; Huang J; Lieu R; Lim S; Lippner D; Obungu V; Ward-Kavanagh L; Weichert K; Ware CF; Vendel AC
    Structure; 2023 Aug; 31(8):958-967.e3. PubMed ID: 37279757
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased Heterologous Protein Expression in Drosophila S2 Cells for Massive Production of Immune Ligands/Receptors and Structural Analysis of Human HVEM.
    Liu W; Vigdorovich V; Zhan C; Patskovsky Y; Bonanno JB; Nathenson SG; Almo SC
    Mol Biotechnol; 2015 Oct; 57(10):914-22. PubMed ID: 26202493
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CD8 T cell memory to a viral pathogen requires trans cosignaling between HVEM and BTLA.
    Flynn R; Hutchinson T; Murphy KM; Ware CF; Croft M; Salek-Ardakani S
    PLoS One; 2013; 8(10):e77991. PubMed ID: 24205056
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HVEM, a cosignaling molecular switch, and its interactions with BTLA, CD160 and LIGHT.
    Rodriguez-Barbosa JI; Schneider P; Weigert A; Lee KM; Kim TJ; Perez-Simon JA; Del Rio ML
    Cell Mol Immunol; 2019 Jul; 16(7):679-682. PubMed ID: 31160757
    [No Abstract]   [Full Text] [Related]  

  • 38. Attenuating lymphocyte activity: the crystal structure of the BTLA-HVEM complex.
    Compaan DM; Gonzalez LC; Tom I; Loyet KM; Eaton D; Hymowitz SG
    J Biol Chem; 2005 Nov; 280(47):39553-61. PubMed ID: 16169851
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Herpesvirus Entry Mediator Binding Partners Mediate Immunopathogenesis of Ocular Herpes Simplex Virus 1 Infection.
    Park SJ; Riccio RE; Kopp SJ; Ifergan I; Miller SD; Longnecker R
    mBio; 2020 May; 11(3):. PubMed ID: 32398314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sirolimus-based regimen promotes inhibitory costimulatory signal of HVEM/BTLA/CD160/LIGHT pathway in allo-renal recipients.
    Bai Y; Shi Y; Li Y; Cai B; Zou Y; Wang L
    Transpl Immunol; 2013 Jan; 28(1):38-47. PubMed ID: 23165214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.